Existing Account

Please login first to complete purchase/ quotation request, view custom order reports, or create favorites list.

Customer ID:
Stay Logged In

Forgot your Customer ID or Password?
New Account

Don't have an account with us yet? Please set up an account to place order or obtain customer services.

Peptides  >  Cancer Research Peptides  >>  VEGFR2/KDR Antagonist

Product Name VEGFR2/KDR Antagonist
Size 1 mg
Catalog # AS-60628
US$ $127
Purity % Peak Area By HPLC ≥ 95%

This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.

Detailed Information Material Safety Data Sheets (MSDS)
Storage -20C
References Ref: Renno, R. et al. Invest. Ophthalmol. Vis. Sci. 43, 3977 (2002); Brekken, R. et al. Cancer Res. 60, 5117 (2000); Jia, H. et al. J. Biol. Chem. 279, 36148 (2004); Ye, F. Gynecol. Oncol. 94, 125 (2004); Bin?truy-Tournaire, R. et al. EMBO J. 19, 1525 (2000).
Molecular Weight 840
(One-Letter Code)
(Three-Letter Code)
H - Ala - Thr - Trp - Leu - Pro - Pro - Arg - OH
Product Citations Renno, RZ. et al. (2004). Selective photodynamic therapy by targeted Verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 122, 1002. doi:10.1001/archopht.122.7.1002.

Liu, H, et al. (2013). Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF/VEGFR2 pathway. Invest Ophthalmol Vis Sci 54, 918. doi: 10.1167/iovs.12-11291.
  < Back